ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Valentin Hammoudi contributed 14 entries already.
California-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
Swedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. Voima Ventures and Nordic Science Investments led the private financing. Illumina Ventures, Almi Invest, Life Science Invest and several genomics-focused private investors also participated.
French biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet need.
Aerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was co-led by EQT Life Sciences through its LSP Dementia Fund, alongside age1, and brings the company’s total funding to €50 million since its seed round in October 2025.
French biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. The deal strengthens Ipsen’s early-stage neuroscience pipeline while giving Origami a potential path toward global development and commercialization
Paris-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices.
Belgian investment company Gimv is drawing a clear line under one chapter of its history. The firm announced via a press release that it will stop making new investments in life sciences and instead focus on four core platforms: consumer, healthcare, smart industries and sustainable cities, alongside its long-term investment program Anchor. The board framed the move as part of a sharper focus on long-term priorities and growth opportunities linked to digital transformation.
Genmab has stopped enrolling patients in an early-stage clinical trial for an experimental cancer drug it gained through the acquisition of ProfoundBio in April 2024 for €1.52 billion. This pause underscores a broader reshaping of its oncology strategy.
GSK has agreed to acquire California-based RAPT Therapeutics in a deal valued at $2.2 billion (€ 1.88 billion), expanding its respiratory, immunology and inflammation portfolio with a late-stage food allergy candidate. The transaction gives GSK global rights to ozureprubart, a long-acting anti-IgE monoclonal antibody now in phase IIb clinical development.
The Novo Nordisk Foundation has committed up to DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII), a Copenhagen-based hub for life science and deep tech entrepreneurship. The long-term funding, running from 2026 to 2035, aims to strengthen Denmark’s innovation capacity while helping Europe turn scientific excellence into companies, jobs and solutions.